Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The company’s shares closed yesterday at p10,794. ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This C$820M investment underscores Ontario’s growing prominence in the life sciences ...

Shares of AstraZeneca PLC AZN inched up 0.05% to £110.46 Thursday, on what proved to be an all-around positive trading ...

AstraZeneca (NASDAQ:AZN ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...

Shares of AstraZeneca PLC AZN inched up 0.04% to £110.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.73% to 8,502.35.

Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

At AstraZeneca, an early adopter of AI and data ... way we discover and design medicines," says Weatherall. “The use is no longer an 'add on' or 'nice to have,' but an essential and integrated ...